Health Care [ 7/12 ] | Biotechnology [ 35/73 ]
NASDAQ | Common Stock
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome.
It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 5, 25 | -1.17 Increased by +23.03% | -1.30 Increased by +10.00% |
| Apr 30, 25 | -1.57 Increased by +22.66% | -1.75 Increased by +10.29% |
| Feb 13, 25 | -1.39 Increased by +8.55% | -1.27 Decreased by -9.45% |
| Nov 5, 24 | -1.40 Increased by +37.22% | -1.45 Increased by +3.45% |
| Aug 1, 24 | -1.52 Increased by +32.44% | -1.69 Increased by +10.06% |
| May 2, 24 | -2.03 Increased by +12.88% | -1.73 Decreased by -17.34% |
| Feb 15, 24 | -1.52 Increased by +29.63% | -1.62 Increased by +6.17% |
| Nov 2, 23 | -2.23 Increased by +36.29% | -2.08 Decreased by -7.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 139.29 M Increased by +27.99% | -151.08 M Increased by +11.49% | Decreased by -108.46% Increased by +30.84% |
| Dec 31, 24 | 164.88 M Increased by +29.42% | -133.38 M Decreased by -8.28% | Decreased by -80.90% Increased by +16.34% |
| Sep 30, 24 | 139.49 M Increased by +42.27% | -133.52 M Increased by +16.37% | Decreased by -95.71% Increased by +41.21% |
| Jun 30, 24 | 147.03 M Increased by +35.75% | -131.60 M Increased by +17.66% | Decreased by -89.51% Increased by +39.34% |
| Mar 31, 24 | 108.83 M Increased by +8.30% | -170.68 M Decreased by -4.09% | Decreased by -156.83% Increased by +3.88% |
| Dec 31, 23 | 127.39 M Increased by +23.27% | -123.19 M Increased by +18.86% | Decreased by -96.70% Increased by +34.18% |
| Sep 30, 23 | 98.05 M Increased by +8.10% | -159.65 M Increased by +34.87% | Decreased by -162.82% Increased by +39.75% |
| Jun 30, 23 | 108.31 M Increased by +21.23% | -159.83 M Decreased by -1.05% | Decreased by -147.57% Increased by +16.64% |